NeoPhore, the cancer immunology company, has announced the appointment of Dr John Haurum as non-executive director with immediate effect.
He was previously chief executive officer of F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer. Under his leadership, F-star successfully raised €200 million in equity and non-dilutive funding.
Robert James, chairman of NeoPhore, commented: “I would like to welcome John to the Neophore Board. John has an excellent track record of building and growing companies in the biotech industry and his expertise and scientific understanding of the IO space will be invaluable as we maximise the potential of our platform.”
